Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC) designed to target cancers overexpressing folate receptor alpha (FRα). It consists of the humanized anti-FRα antibody Farletuzumab, linked to the cytotoxic drug eribulin via a cleavable Mal-PEG2-Val-Cit-PAB linker. The drug has an drug-to-antibody (DAR) ratio of 4.0, allowing efficient delivery of eribulin to cancer cells.
Key Features
- Targeted Delivery: Specifically binds to FRα, ensuring the drug reaches cancer cells.
- Strong Effectiveness: Highly toxic to FRα-positive cancer cells in lab tests.
- Potent Tumor Reduction: Shows significant ability to shrink tumors in FRα-positive cancers.
- Controlled Release: Uses a linker that activates only inside cancer cells, protecting healthy tissues.
Clinical Development
Farletuzumab ecteribulin has shown promising results in clinical trials for FRα-positive cancers. In patients with platinum-resistant ovarian cancer, it reduced tumors effectively and caused manageable side effects, especially at higher doses.
Applications
- Ovarian Cancer: Effective for FRα-positive and platinum-resistant ovarian cancer.
- Endometrial Cancer: Investigated for treating FRα-positive endometrial cancers.
- Non-Small Cell Lung Cancer: Explored for potential use in FRα-positive lung cancer.
Farletuzumab ecteribulin offers a powerful and precise treatment option for cancers that express folate receptor alpha, with the potential to improve outcomes for patients.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.